Federal Cannabis Rescheduling 2026: Medical Marijuana Moves to Schedule III Under Trump — What’s Next for Legal Weed

The battle for legal cannabis at the federal level just hit its most concrete shift in decades. As of August 2026, state-licensed medical marijuana and FDA-approved cannabis products sit in Schedule III of the Controlled Substances Act. Adult-use cannabis remains Schedule I. Here’s exactly where the fight stands right now.

The Big Change: Medical Cannabis Rescheduled in April 2026

On April 23, 2026, Acting Attorney General Todd Blanche signed a final order placing two categories of cannabis into Schedule III:

• FDA-approved drug products containing marijuana
• Marijuana grown, manufactured, distributed, or dispensed under a qualifying state medical marijuana license

This followed President Trump’s December 18, 2025 Executive Order 14370 directing the Attorney General to complete rescheduling “in the most expeditious manner.” The order took effect with Federal Register publication around April 28, 2026.

Immediate results for medical operators:

• IRS Section 280E no longer blocks ordinary business deductions for qualifying state-licensed medical businesses
• Research barriers drop significantly
• State medical licensees gained a pathway to DEA registration

This is the first time federal law has formally acknowledged accepted medical use for these products in nearly a century.

What Did Not Change

Adult-use and recreational cannabis remains Schedule I. Unlicensed bulk material stays Schedule I. Federal criminal penalties, interstate commerce bans, and most banking restrictions continue. Rescheduling is not legalization. Possession, distribution, and sale of non-covered cannabis still violate federal law.

The Broader Rescheduling Hearing

Alongside the medical order, the DEA restarted the administrative process on the 2024 proposed rule to move all marijuana to Schedule III. Hearings ran June 29 through July 15, 2026. For the first time, the federal government itself argued in favor of broader rescheduling.

Post-hearing briefs were due around mid-August 2026. The Administrative Law Judge will issue a non-binding recommendation. The final decision rests with the DEA Administrator. Legal challenges to the April medical order remain pending in the D.C. Circuit.

Congress and Banking Access

The SAFE Banking Act of 2026 was reintroduced on a bipartisan basis in both the House and Senate in late June 2026. The bill would protect banks and credit unions that serve state-legal cannabis businesses. It has passed the House multiple times in previous Congresses but has never cleared the Senate. As of early August 2026 it remains in committee.

No full descheduling or federal legalization bill has advanced meaningfully this session.

Why This Matters in August 2026

Medical cannabis now operates under a clearer federal framework with real tax relief. Research doors are opening. Adult-use markets still face the full Schedule I conflict. The next decisive steps are the ALJ recommendation, the DEA’s final rule on broader rescheduling, the outcome of D.C. Circuit litigation, and whether Congress finally moves on banking protections.

State-legal medical programs just gained the strongest federal foothold they have ever had. Adult-use reform remains unfinished business.

Bottom line: Federal cannabis policy moved from stagnation to partial progress under the Trump administration in 2026. Medical is Schedule III. Adult-use is still waiting. The fight continues.